Sign In
Buy MASI
$179.95
+0 (+0%)
At Close: Jun 23, 2026
Wall Street Breakfast Podcast: Masimo Jumps As Danaher Nears $10B Deal
06:49am, Tuesday, 17'th Feb 2026
Danaher (DHR) is nearing a ~$10B acquisition of Masimo (MASI), representing a significant premium to MASI's prior $7B market cap. Elliott Investment Management has built a >10% stake in Norwegian Crui
Danaher Strikes $10 Billion Deal for Masimo
06:09am, Tuesday, 17'th Feb 2026
The medical-device maker is expected to operate as a stand-alone company within Danaher's Diagnostics segment.
Masimo Stock Soars As Danaher Closes In On Blockbuster Deal
05:46am, Tuesday, 17'th Feb 2026
Danaher approaches a $9.9 billion acquisition of Masimo following activist-led board changes and recent divestitures.
Stock Market Today: Dow Futures Gain, Nasdaq Drags—ZIM Integrated Shipping, Masimo, Toll Brothers In Focus
05:26am, Tuesday, 17'th Feb 2026
U.S. stock futures fluctuated on Tuesday following Friday's mixed close. Futures of major benchmark indices were mixed at the beginning of the holiday-shortened week as the markets were closed on Mond
Danaher closes in on nearly $10 billion deal for Masimo, FT reports
11:11pm, Monday, 16'th Feb 2026
US healthcare manufacturer Danaher is closing in a nearly $10 billion deal to acquire medical technology company Masimo , the Financial Times reported on Monday, citing people familiar with the matter
Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26
09:00am, Thursday, 12'th Feb 2026
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, Febru
Masimo Corporation (NASDAQ:MASI) Given Average Rating of “Hold” by Analysts
03:10am, Thursday, 05'th Feb 2026
Shares of Masimo Corporation (NASDAQ: MASI - Get Free Report) have been assigned a consensus rating of "Hold" from the eight ratings firms that are currently covering the firm, MarketBeat Ratings repo
Here's Why You Should Add Masimo Stock to Your Portfolio Now
01:55pm, Wednesday, 04'th Feb 2026
MASI targets 7%-10% revenue growth through 2028, sharp margin expansion and rising cash flow as intelligent monitoring and partnerships gain traction.
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 04'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Townsquare Capital LLC Decreases Stock Position in Masimo Corporation $MASI
04:43am, Sunday, 01'st Feb 2026
Townsquare Capital LLC reduced its holdings in shares of Masimo Corporation (NASDAQ: MASI) by 70.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange C
Owlet vs. Masimo: Which Medical Monitoring Stock Is the Better Buy?
10:51am, Thursday, 29'th Jan 2026
Remote and continuous patient monitoring is moving from a niche capability to a core pillar of modern healthcare, driven by aging populations, staffing shortages, and a push toward data-driven care bo
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
01:10pm, Tuesday, 27'th Jan 2026
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Think Masimo (MASI) Could Surge 31.06%: Read This Before Placing a Bet
10:56am, Tuesday, 27'th Jan 2026
The consensus price target hints at a 31.1% upside potential for Masimo (MASI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
FMS or MASI: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 26'th Jan 2026
Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?
Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board
04:30pm, Wednesday, 21'st Jan 2026
BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD
